ABSTRACT
Hospitalizations for acute cardiac conditions have markedly declined during the coronavirus disease 2019 (COVID-19) pandemic, yet the cause of this decline is not clear. Using remote monitoring data of 4,029 patients with implantable cardiac defibrillators (ICDs) living in New York City and Minneapolis/Saint Paul, we assessed changes in markers of cardiac status among these patients and compared thoracic impedance and arrhythmia burden in 2019 and 2020 from January through August. We found no change in several key disease decompensation markers among patients with implanted ICD devices during the first phase of COVID-19 pandemic, suggesting that the decrease in cardiovascular hospitalizations in this period is not reflective of a true population-level improvement in cardiovascular health.
INTRODUCTION
During the coronavirus disease 2019 (COVID-19) pandemic, hospitalizations for acute cardiac conditions including heart failure have markedly declined.1, 2 This may be because patients are avoiding seeking care during the pandemic or because cardiovascular events are fewer due to changes in behaviors or exposures. Implantable cardiac defibrillators (ICDs) implanted in patients with heart failure provide useful information on markers of cardiac status as measured by thoracic impedance, arrhythmia burden, and device discharges.3 Using remote monitoring data of patients with ICDs living in New York City (NYC) and Minneapolis/Saint Paul (MSP), we sought to assess changes in markers of cardiac status among these patients and compared thoracic impedance and arrhythmia burden in 2019 and 2020 from January through August.
METHODS
A de-identified dataset of individuals from NYC and MSP aged ≥18 years with ICD devices transmitting between January 1st, 2019 and August 22nd, 2020 was derived from the Boston Scientific Corporation’s LATITUDE™ database. Measured variables included daily thoracic impedance, nighttime heart rate, respiration rate, heart rate variability, time in atrial fibrillation (AF), percentages of patients with AF time greater than 1 hour, and HeartLogic index for heart failure decompensation. For this analysis, we used remote monitoring data exclusively from scheduled data uploads to eliminate potential bias in event-based data uploads.
We assessed the trend in daily thoracic impedance, arrhythmia burden, and device discharges between January 1st, 2020 and August 22nd, 2020. We used data during the same period from 2019 as a baseline to account for seasonal variability and then calculated the change in these variables during and after COVID-19 restrictions in 2020. Year to year comparisons for the same time period were performed using a repeated measures ANOVA. We considered 2-sided P-values <0.05 as statistically significant. Analyses were performed using R version 4.0.2 (CRAN institute). This study was approved by the Institutional Review Board at Yale University.
RESULTS
A total of 4,029 patients were included in the analysis, of whom 2,792 were from NYC (mean age 67.9 [SD, 13.5] years; 31.9% women) and 1,237 were from MSP (mean age 67.3 [SD, 13.3] years; 28.9% women). There was little to no statistical or clinically meaningful change in thoracic impedance and arrhythmia burden in patients with ICD devices during the COVID-19 shut-down period (Figure). The average daily nighttime heart rate, heart rate variability, and HeartLogic index for heart failure decompensation decreased slightly (relative change less than 5%) from the date that the emergency quarantine order was issued (03/07/20 in NYC and 03/13/20 in MSP) to the end of August. Conversely, average daily thoracic impedance, AF, and percentages of patients with daily AF time greater than 1 hour increased slightly in the same time period. However, none of these changes were statistically significant except for the decrease of heart rate variability in NYC and the increase of AF burden in MSP. Similar trends were seen in both NYC and MSP and were consistent across age and sex subgroups.
DISCUSSION
There is little to no change in most markers for disease decompensation among heart failure patients with implanted ICD devices in NYC and MSP during the COVID-19 pandemic, and this is consistent for all age and sex subgroups. The lack of changes in cardiac status among a high-risk group suggests that the decline in inpatient cardiovascular services was not a result of marked improvement in cardiovascular health.
There may be several explanations for the lack of change. First, the effects of behavioral changes on disease decompensation are not immediate. As such, a brief period of behavioral changes such as reduced physical activity due to lockdown may not result in immediate changes in markers of cardiac status. Second, the effects of behavioral changes may be offset by changed exposures. For example, the loss of physical activity may be compensated for by shifts in dietary patterns and reduced exposure to ambient stressors.
These findings have implications regarding the causes of the decrease in cardiovascular hospitalizations during the shutdown. Media reports expressed concerns that people were avoiding care.4, 5 An alternative hypothesis is that cardiovascular health improved with better air quality and fewer risk behaviors. Our study fails to provide evidence that cardiovascular health improved (or worsened) among people with cardiovascular disease. These findings instead necessitate health care attention and highlight the importance of ensuring high-risk patients have access to critical clinical care during the current COVID-19 pandemic.
Limitations of our study include inability to ascertain clinical outcomes, the lack of information on other factors that may affect disease decompensation markers, and the short follow-up observation period.
In conclusion, we found no change in several key disease decompensation markers among patients with implanted ICD devices during the first phase of COVID-19 pandemic, suggesting that the decrease in cardiovascular hospitalizations in this period is not reflective of a true population-level improvement in cardiovascular health. We will need to remain vigilant to prevent a second pandemic of neglected cardiovascular disease in the coming months.
Data Availability
Aggregate data of the results are available upon request to authors.
Funding
None.
Disclosures
In the past three years, Dr. Krumholz received expenses and/or personal fees from UnitedHealth, IBM Watson Health, Element Science, Aetna, Facebook, the Siegfried and Jensen Law Firm, Arnold and Porter Law Firm, Martin/Baughman Law Firm, F-Prime, and the National Center for Cardiovascular Diseases in Beijing. He is an owner of Refactor Health and HugoHealth, and had grants and/or contracts from the Centers for Medicare & Medicaid Services, Medtronic, the U.S. Food and Drug Administration, Johnson & Johnson, and the Shenzhen Center for Health Information. Dr. Lu is supported by the National Heart, Lung, and Blood Institute (K12HL138037) and the Yale Center for Implementation Science. She was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion. Dr. Murugiah works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs. Mr. Jones and Dr. Ahmed are employees of the Boston Scientific Cooperation. The other co-authors report no potential competing interests.
FIGURE LEGENDS
The left side is New York City, and the right side is Minneapolis/Saint Paul. The dashed line is 2019 and the solid line is 2020.
The vertical line is the date of emergency order and the shaded area is the stay-at-home order for each city.
Abbreviations: HR, heart rate; HRV, heart rate variability; Resp rate, respiration rate; AF, atrial fibrillation.
ACKNOWLEDGEMENTS
